Publications 2013

1. Cambi A, Lakadamyali M, Lidke DS, Garcia-Parajo MF. Meeting report--Visualizing signaling nanoplatforms at a higher spatiotemporal resolution. J Cell Sci, 2013. 126(Pt 17): 3817-21.

2. Di J, Duiveman-de Boer T, Figdor CG, Torensma R. Aiming to immune elimination of ovarian cancer stem cells. World J Stem Cells, 2013. 5(4): 149-62.

3. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M, European Leukemia N. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 2013. 122(17): 2943-64.

4. Karthaus N, Hontelez S, Looman MW, van Spriel AB, Ansems M, Adema GJ. Nuclear receptor expression patterns in murine plasmacytoid and conventional dendritic cells. Mol Immunol, 2013. 55(3-4): 409-17.

5. Di J, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Massuger LF, Torensma R. The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients. Cell Oncol (Dordr), 2013. 36(5): 363-74.

6. Bull C, Boltje TJ, Wassink M, de Graaf AM, van Delft FL, den Brok MH, Adema GJ. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol Cancer Ther, 2013. 12(10): 1935-46.

7. Srinivas M, Melero I, Kaempgen E, Figdor CG, de Vries IJ. Cell tracking using multimodal imaging. Contrast Media Mol Imaging, 2013. 8(6): 432-8.

8. Tel J, Sittig SP, Blom RA, Cruz LJ, Schreibelt G, Figdor CG, de Vries IJ. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol, 2013. 191(10): 5005-12.

9. Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, Epling-Burnette P, Van Bijnen S, Dolstra H, Cannon J, Youn JI, Donatelli SS, Qin D, De Witte T, Tao J, Wang H, Cheng P, Gabrilovich DI, List A, Wei S. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest, 2013. 123(11): 4595-611.

10. Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schonland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kroger N, Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for B, Marrow T. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 2013. 48(11): 1395-400.

11. Nicolaie MA, van Houwelingen JC, de Witte TM, Putter H. Dynamic prediction by landmarking in competing risks. Stat Med, 2013. 32(12): 2031-47.

12. Di J, Massuger LF, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Torensma R. Functional OCT4-specific CD4 and CD8 T cells in healthy controls and ovarian cancer patients. Oncoimmunology, 2013. 2(5): e24271.

13. Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJ, Adema GJ, Heerschap A, Figdor CG, Oyen WJ, de Vries IJ. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res, 2013. 19(6): 1525-33.

14. Bol KF, Tel J, de Vries IJ, Figdor CG. Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology, 2013. 2(3): e23431.

15. Kroger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, Milpied N, Volin L, Mohty M, Leblond V, Blaise D, Finke J, Schaap N, Robin M, de Witte T. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia, 2013. 27(3): 604-9.

16. Timmermans K, Plantinga TS, Kox M, Vaneker M, Scheffer GJ, Adema GJ, Joosten LA, Netea MG. Blueprints of signaling interactions between pattern recognition receptors: implications for the design of vaccine adjuvants. Clin Vaccine Immunol, 2013. 20(3): 427-32.

17. van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Drager AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellstrom-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subira D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Bene MC, Westers TM. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma, 2013. 54(3): 472-5.

18. Wolf K, Te Lindert M, Krause M, Alexander S, Te Riet J, Willis AL, Hoffman RM, Figdor CG, Weiss SJ, Friedl P. Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol, 2013. 201(7): 1069-84.

19. Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schonland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kroger N. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood, 2013. 121(25): 5055-63.

20. Schreibelt G, Bol KF, Aarntzen EH, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ. Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. Oncoimmunology, 2013. 2(6): e24440.

21. Basak GW, de Wreede LC, van Biezen A, Wiktor-Jedrzejczak W, Halaburda K, Schmid C, Schaap N, Dazzi F, von dem Borne PA, Petersen E, Beelen D, Abayomi A, Volin L, Buzyn A, Gurman G, Bunjes D, Guglielmi C, Olavarria E, de Witte T. Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplant, 2013. 48(6): 837-42.

22. Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM, Volin L, Bornhauser M, Robin M, Rocha V, de Witte T, Kroger N, Mohty M. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with . Bone Marrow Transplant, 2013. 48(6): 761-70.

23. Paulis LE, Mandal S, Kreutz M, Figdor CG. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr Opin Immunol, 2013. 25(3): 389-95.

24. Aarntzen EH, Srinivas M, Schreibelt G, Heerschap A, Punt CJ, Figdor CG, Oyen WJ, de Vries IJ. Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. Oncoimmunology, 2013. 2(7): e24661.

25. Aarntzen EH, Srinivas M, Radu CG, Punt CJ, Boerman OC, Figdor CG, Oyen WJ, de Vries IJ. In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cell Mol Life Sci, 2013. 70(13): 2237-57.

26. Blijlevens N, de Chateau M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant, 2013. 48(7): 966-71.

27. van den Dries K, Schwartz SL, Byars J, Meddens MB, Bolomini-Vittori M, Lidke DS, Figdor CG, Lidke KA, Cambi A. Dual-color superresolution microscopy reveals nanoscale organization of mechanosensory podosomes. Mol Biol Cell, 2013. 24(13): 2112-23.

28. Moghadasali R, Mutsaers HA, Azarnia M, Aghdami N, Baharvand H, Torensma R, Wilmer MJ, Masereeuw R. Mesenchymal stem cell-conditioned medium accelerates regeneration of human renal proximal tubule epithelial cells after gentamicin toxicity. Exp Toxicol Pathol, 2013. 65(5): 595-600.

29. van den Dries K, Meddens MB, de Keijzer S, Shekhar S, Subramaniam V, Figdor CG, Cambi A. Interplay between myosin IIA-mediated contractility and actin network integrity orchestrates podosome composition and oscillations. Nat Commun, 2013. 4: 1412.

30. Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 2013. 121(3): 459-67.

31. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, Schadendorf D, Croockewit A, Blokx WA, Van Rossum MM, Kwok WW, Adema GJ, Punt CJ, Figdor CG. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res, 2013. 73(1): 19-29.

32. van Spriel AB, de Jong EC. Dendritic cell science: more than 40 years of history. J Leukoc Biol, 2013. 93(1): 33-8.

33. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M, Winkels G, Coulie PG, Punt CJ, Figdor CG, de Vries IJ. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res, 2013. 73(3): 1063-75.

34. Aarntzen E, Srinivas M, Figdor C, Oyen W, DeVries IJM. FLT-PET imaging for early identification of antigen-specific immune responses in cancer patients. Journal of Nuclear Medicine, 2013. 54: 30-1.

35. Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M, Fritzsche K, Haas P, Salih HR, Giagounidis A, Selleslag D, Labar B, de Witte T, Wijermans P, Lubbert M. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica, 2013. 98(2): 208-16.

36. Hobo W, Broen K, van der Velden WJ, Greupink-Draaisma A, Adisty N, Wouters Y, Kester M, Fredrix H, Jansen JH, van der Reijden B, Falkenburg JH, de Witte T, Preijers F, Schattenberg T, Feuth T, Blijlevens NM, Schaap N, Dolstra H. Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant, 2013. 19(2): 274-82.

37. Gilsanz A, Sanchez-Martin L, Gutierrez-Lopez MD, Ovalle S, Machado-Pineda Y, Reyes R, Swart GW, Figdor CG, Lafuente EM, Cabanas C. ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9. Cell Mol Life Sci, 2013. 70(3): 475-93.

38. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 2013. 138(2): 105-15.

39. Meddens MB, Rieger B, Figdor CG, Cambi A, van den Dries K. Automated podosome identification and characterization in fluorescence microscopy images. Microsc Microanal, 2013. 19(1): 180-9.

40. Chokkalingam V, Tel J, Wimmers F, Liu X, Semenov S, Thiele J, Figdor CG, Huck WT. Probing cellular heterogeneity in cytokine-secreting immune cells using droplet-based microfluidics. Lab Chip, 2013. 13(24): 4740-4.

41. Amadori S, Suciu S, Stasi R, Salih HR, Selleslag D, Muus P, De Fabritiis P, Venditti A, Ho AD, Lubbert M, Thomas X, Latagliata R, Halkes CJ, Falzetti F, Magro D, Guimaraes JE, Berneman Z, Specchia G, Karrasch M, Fazi P, Vignetti M, Willemze R, de Witte T, Marie JP. Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). J Clin Oncol, 2013. 31(35): 4424-30.

42. de Witte T. Iron chelators in myelodysplastic syndrome: To lower ferritin levels or to improve survival?. Leuk Res, 2013. 37(12): 1605.

43. Nierkens S, Tel J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic cell subsets: one general or all sergeants?. Trends Immunol, 2013. 34(8): 361-70.

44. Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N, Dolstra H. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother, 2013. 62(8): 1381-92.

45. Kreutz M, Tacken PJ, Figdor CG. Targeting dendritic cells--why bother?. Blood, 2013. 121(15): 2836-44.

46. Hontelez S, Karthaus N, Looman MW, Ansems M, Adema GJ. DC-SCRIPT regulates glucocorticoid receptor function and expression of its target GILZ in dendritic cells. J Immunol, 2013. 190(7): 3172-9.

47. Torensma R, Prins HJ, Schrama E, Verwiel ET, Martens AC, Roelofs H, Jansen BJ. The impact of cell source, culture methodology, culture location, and individual donors on gene expression profiles of bone marrow-derived and adipose-derived stromal cells. Stem Cells Dev, 2013. 22(7): 1086-96.

48. van Gelder M, de Wreede LC, Schetelig J, van Biezen A, Volin L, Maertens J, Robin M, Petersen E, de Witte T, Kroger N. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. Leukemia, 2013. 27(4): 879-88.

49. Gartlan KH, Wee JL, Demaria MC, Nastovska R, Chang TM, Jones EL, Apostolopoulos V, Pietersz GA, Hickey MJ, van Spriel AB, Wright MD. Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol, 2013. 43(5): 1208-19.

50. Bol K, Schreibelt G, Aarntzen EA, De Vries IJ, Figdor C. 2013. Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. In Cancer Immunotherapy, ed. TJ Curiel, pp. 71-108. New York: Springer Science + Business Media .

51. Nierkens S, den Brok M, Ruers T, Adema GJ. 2013. Radiofrequency Ablation in Cancer Therapy: Tuning in to in situ Tumor Vaccines. In Tumor Ablation, the Tumor Mircorenvironment, ed. Y Keisari, pp. 39-59. Dordrecht: Springer Science + Business Media.

52. Snaar-Jagalska BE, Cambi A, Schmidt T, de Keijzer S. Single-molecule imaging technique to study the dynamic regulation of GPCR function at the plasma membrane. Methods in enzymology, 2013. 521: 47-67.

53. Bakdash G, Sittig SP, van Dijk T, Figdor CG, de Vries IJ. The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol, 2013. 4: 53.

54. De Keijzer S, Meddens MB, Torensma R, Cambi A. The Multiple Faces of Prostaglandin E2 G-Protein Coupled Receptor Signaling during the Dendritic Cell Life Cycle. Int J Mol Sci, 2013. 14(4): 6542-55.

55. Schulte BM, Kers-Rebel ED, Prosser AC, Galama JM, van Kuppeveld FJ, Adema GJ. Differential susceptibility and response of primary human myeloid BDCA1(+) dendritic cells to infection with different Enteroviruses. PLoS One, 2013. 8(4): e62502.

56. Schaft N, Coccoris M, Drexhage J, Knoop C, de Vries IJ, Adema GJ, Debets R. An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8alpha Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT. Front Immunol, 2013. 4: 270.

57. Bekkering S, Torensma R. Another look at the life of a neutrophil. World J Hematol, 2013. 2(2): 44-58.

58. Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L, Robin M, van Gelder M, Finke J, Bornhauser M, Kobbe G, Germing U, de Witte T, Kroger N. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. PLoS One, 2013. 8(10): e74368.

59. Srinivas M, Boehm-Sturm P, Aswendt M, Pracht ED, Figdor CG, de Vries IJ, Hoehn M. In vivo 19F MRI for cell tracking. J Vis Exp, 2013. (81): e50802.

60. Mathan TS, Figdor CG, Buschow SI. Human plasmacytoid dendritic cells: from molecules to intercellular communication network. Front Immunol, 2013. 4: 372.

61. Vasaturo A, Di Blasio S, Peeters DG, de Koning CC, de Vries JM, Figdor CG, Hato SV. Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol, 2013. 4: 417.

62. Van Bijnen S, Ffrench M, Kruijt N, de Witte T, Hebeda KM, Muus P. Bone marrow histology in patients with a paroxysmal nocturnal hemoglobinuria clone correlated with clinical parameters.. J of Hematopahtol, 2013. 6(2): 71-82.

63. Mandal S, Eksteen-Akeroyd ZH, Jacobs MJ, Hammink R, Koepf M, Lambeck AJA, van Hest JCM, Wilson CJ, Blank K, Figdor CG, Rowan AE. Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy. Chemical Science, 2013. 4(11): 4168-74.